



Sharewise – Live Investor Webinar

Melbourne, Australia, 25 July 2024 – InhaleRx Ltd (ASX: IRX), ('**IRX** 'or '**the Company**') an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors is pleased to announce IRX's CEO, Darryl Davies, will be appearing on a live webinar hosted by **Sharewise** at 2pm AEST today, Thursday, 25 July 2024.

The webinar will commence with a presentation, followed by a live Q&A with the audience, providing attendees the opportunity to ask the CEO any questions about IRX they may have.

Shareholders wishing to attend can register online at the following link: <https://hubs.la/Q02H2RgW0>

A copy of the presentation being given is attached.

A promotional graphic for the ASX:IRX Webinar. It features a light blue and white background. On the right is a portrait of Darryl Davies, CEO of InhaleRx, smiling and wearing a light-colored suit. On the left, the text "ASX:IRX" is in blue, followed by "WEBINAR" in large, bold, black letters. Below this, a pink box contains "Darryl Davies / CEO". The InhaleRx logo is displayed below. At the bottom left, three circular icons represent a calendar, a clock, and a box of pills, with corresponding text: "25 JUL 2024", "2PM AEST", and "HEALTH CARE EQUIPMENT & SERVICES". The Sharewise logo, featuring an owl icon and the word "sharewise", is in the top right corner.

InhaleRx Limited (ACN 611 845 820)
Level 9
505 Little Collins Street
Melbourne VIC 3000
Phone: +61 3 8678 4091

Authorised by the Board of Directors.

For further information:

www.inhalerx.com.au

James Barrie, Company Secretary

Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company's shareholders, the first medical indications under investigation are Breakthrough Cancer Pain (BTcP) and Panic Disorder (PD), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.

DEVELOPING TOMORROW'S INHALED THERAPIES

DISCLAIMER

This presentation contains summary information about InhaleRx Limited ("InhaleRx" or "IRX" or "Company") and its activities current as at the date of this presentation. It should be read in conjunction with InhaleRx' other periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire InhaleRx shares or other securities. It has been prepared without taking into account the objectives, financial situation or needs of individuals.

Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek legal and taxation advice appropriate to their jurisdiction. Past performance is no guarantee of future performance.

No representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of InhaleRx and its related bodies corporate, or their respective directors, employees or agents, nor any other person accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence.

This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to InhaleRx' business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words 'plan', 'will', 'anticipate', 'expect', 'may', 'should' and similar expressions, as they relate to InhaleRx and its management, are intended to identify forward-looking statements.

Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of InhaleRx to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.

ABOUT INHALERX

InhaleRx Limited (ASX: IRX) is a clinical stage biotechnology development company focused on **developing innovative inhaled therapeutics to address unmet medical needs in pain management and mental health treatment.**




Two drug candidates in development



Provisional patents lodged



Rapid Onset Drug Devices



Innovation patent for inhalation of synthetic cannabinoids approved



Multiple Phase I/II and Phase II/III Clinical Trials



Supportive Safety Data

AGILE AND EXPERIENCED TEAM



Darryl Davies

Chief Executive Officer

Over 17 years experience in clinical psychology, harm minimisation and healthcare commercialisation.

Drug development specialist with marketing that specialises in sponsor onboarding and clinical operational excellence.

Cross over experience as a co-founder of Ingenu CRO.

Cross border Board Director experience (ASX, NZX, etc).



Dr. Rob Jenny

Chief Scientific Officer

A PhD-level scientist by training with significant experience in the commercialisation of research, project management, manufacturing, and business development.

Significant product development and GMP manufacturing experience.

Scientific, regulatory affairs, medical writing, and early-phase clinical drug development experience.



Sean Williams

Non-Executive Chairman

Senior executive who has had a successful career across the supply chain, health, pharmaceutical and investment management sectors.

Experience as CEO of investment company with Assets Under Management of \$475m+.

Ex- General Manager Finance and General Manager – Hospital Pharmacy & Dental Distribution Services for Symbion Pharmacy Services.



Dr. Andrew Saich

Non-Executive Director

UK trained physician with a degree in physiology and a degree in medicine from the University of London.

Vast experience within the pharmaceutical and medical cannabis industries as a Senior Executive leading the medical team at GW Pharmaceuticals.

Chief Medical Officer at Senzer Pharmaceuticals & European Medical Director for Intercept Pharmaceuticals.



Dr. Sud Agarwal

Medical Advisor

Globally recognised FDA specialist drug development expert..

Uk, and Australian trained medical professional, with a wealth of experience in the medical, and healthcare commercialisation field.


Board Certified Specialist Anesthesiologist since 2009.

Chief Executive Officer of iNGENē CRO, with asx and NASDAQ Board experience.

OUR STRATEGY




Focus on Pain
Management



Focus on Inhalation Drug
Device Development



Focus on Mental Health




Focus on operational
execution

OUR APPROACH



Speed to market



Agile and responsive to
pivot opportunities



Pursuing the path of least
resistance

WHY INHALED THERAPIES

Fast speed of onset

peak effect in ~4 mins vs ~2 hours for oral

Higher bioavailability


>60% vs 5-9% for oral

Ease of use

Targeting acute symptoms and potentially avoiding unnecessary long-term medicating


	Inhaled	Oral	Transdermal	Injectable
Onset of Action [^]	Fast	Slow	Slow	Fast
Offset of Action [^]	Fast	Slow	Slow	Fast
Bioavailability	High	Low	Low	High
Not impacted by 1st pass metabolism	✓	✗	✓	✓
Ease of patient use	✓	✓	✓	✗
Suitable for Acute Indications	✓	✗	✓	✓

EFFICIENT DRUG DELIVERY



INHALATION

- Rapid absorption 3-5 mins to peak blood level
- Transient effect
- **More efficient**



ORAL

- Slow absorption + metabolism by liver 60-150mins to peak blood level
- Sustained effect (incl. side effects)
- **Less efficient**

THE OPIOID CRISIS


In 2018, the FDA put in place strict Risk Mitigation Strategies (REMS) for prescribing rapid-acting fentanyl products.

Harms must be weighed by side effects and drug misuse which are indirect costs to society and patients.

Reasons for limiting the use of fentanyl in clinical practice incl. side effects, mortality, abuse potential, marginal clinical benefit and high cost.



Three Waves of Opioid Overdose Deaths



DEVELOPING IRX-211 AS A THERAPEUTIC AGENT



IRX-211 will be a registered prescription-only medication to treat Breakthrough Cancer Pain.




Resources deployed to clinical trials to show safety and efficacy.




Regulatory approval(s) will allow InhaleRx to make a marketing claim.



Access to government reimbursements + regulatory levers creates a strong commercial and competitive position






THE MENTAL HEALTH CRISIS

Sharp spike in prevalence: the lifetime prevalence of Panic Disorder ranges from 1.7% to 5% worldwide. Events such as Covid-19 has thought to have significantly increased prevalence of anxiety and depression.

Age of Onset: The median age of onset for Panic Disorder is around 24 years old, as reported by the NCS-R and other epidemiological surveys.

Gender Differences: Epidemiological studies, including those by the National Institute of Mental Health (NIMH), consistently find that women are about twice as likely as men to develop Panic Disorder.



COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide

Wake-up call to all countries to step up mental health services and support

DEVELOPING IRX-616a AS A THERAPEUTIC AGENT



IRX-616a will be a registered prescription-only medication to treat Panic Disorder.



Resources deployed into clinical trials to show safety and efficacy.



Regulatory approval(s) with the FDA will allow InhaleRx to make a marketing claim.



An FDA approval will open up the door to approvals with the EMA and TGA.




No competition in terms of inhaled FDA approved medications to treat PD.




Access to government reimbursements + regulatory levers creates a strong commercial and competitive position.





PATHWAY TO REGISTRATION (FDA NDA)

Following in the footsteps of existing approvals
Leveraging existing data via FDA's 505(b)(2) } reduces risk, time and cost



Time to approval – only 3 to 5 years

REASONS TO CONSIDER BECOMING A SHAREHOLDER

Significant M&A potential with both big pharma and/or big tobacco. .

Loyal investor base - top 20 own more than 75% of the share capital.

Attractive entry point given the correction in the biotech industry over the last 12-18 months.

Positive insights from the data so far, and the medical writing is complete the company prepares for the next stages of clinical development.

Validated pathway from the FDA via the PIND meetings to define the targeted primary endpoints.

Plans developed and quotes acquired extending to the Phase 3 multinational studies.

\$5.31m*

Market Cap

\$0.028*

Share Price

**Data accurate as of July 24th 2024*

THANK YOU

I welcome any further questions you may have

Darryl Davies
darryl.davies@inhalerx.com.au